Interpreting discordance on dual-tracer positron emission tomography–computed tomography in the setting of metastatic neuroendocrine tumor: Detection of metachronous triple-negative breast carcinoma.

Second primary malignancies (SPMs) are known to be associated with neuroendocrine tumors (NETs). The association necessitates a careful assessment of the dual-tracer positron emission tomography–computed tomography (PET-CT) imaging findings to identify these malignancies earlier. Such early diagnosis can provide incremental benefit for screening these SPMs apart from their known applications in the management of NETs. A case of incidentally detected metachronous triple-negative breast carcinoma on dual-tracer PET-CT imaging is presented using ¹⁸fluoro-2-deoxy-D-glucose (FDG) and ⁶⁸Ga-DOTATATE that showed a high uptake on FDG but no uptake on somatostatin receptor-based imaging. [ABSTRACT FROM AUTHOR]